Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder
Brief Summary: Cognitive-behavioral therapy (CBT) has proven efficacy for treatment of pediatric obsessive-compulsive disorder (OCD). Yet, CBT does not help all children and those who benefit often remain symptomatic upon treatment completion. Recent clinical trials in adults with other anxiety disorders (acrophobia and social phobia) provided support for using a medication called D-Cycloserine (DCS) to enahnce the outcome of exposure-based psychotherapy. Given this, DCS may augment CBT in youth with OCD, an anxiety disorder that is conceptually similar to acrophobia. With this in mind, the investigators are conducting a randomized, double-blind placebo controlled pilot study of DCS to determine whether it had any short-term clinical benefits on CBT in youth with OCD. Forty children and adolescents (ages 8-17) with a primary diagnosis of OCD will be screened and, should they meet relevant criteria, randomly assigned to one of two treatment conditions: (1) CBT plus DCS, or (2) CBT plus placebo. All patients will receive 10 sessions of CBT A rater will assess participants at 3 separate time points.


Options:
A: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Individual Cognitive Behavioral Therapy (CBT), Drug: Placebo | Arm Label: D-Cycloserine; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Cognitive Behavioral Therapy (CBT), Drug: D-Cycloserine | Intervention Type: BEHAVIORAL; Name: Individual Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): D-Cycloserine, Sugar Pill | Intervention Type: DRUG; Name: D-Cycloserine; Assigned to Arm(s): D-Cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar Pill
B: Arm Label: Cognitive-behavioral therapy + placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive-behavioral therapy, Drug: Placebo pill | Arm Label: Cognitive-behavioral therapy + D-cycloserine; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy, Drug: D-cycloserine | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): Cognitive-behavioral therapy + D-cycloserine, Cognitive-behavioral therapy + placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): Cognitive-behavioral therapy + D-cycloserine | Intervention Type: DRUG; Name: Placebo pill; Assigned to Arm(s): Cognitive-behavioral therapy + placebo
C: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): N/A
D: Arm Label: D-cycloserine plus exposure therapy; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine, Behavioral: Exposure therapy | Arm Label: Placebo plus exposure therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Exposure therapy, Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine plus exposure therapy | Intervention Type: BEHAVIORAL; Name: Exposure therapy; Assigned to Arm(s): D-cycloserine plus exposure therapy, Placebo plus exposure therapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus exposure therapy

Answer: B